Tim Lowery Promoted to President of JSR Life Sciences, LLC
JSR Life Sciences, LLC announced today that Tim Lowery has assumed the role of president where he will oversee the Company’s global operations, which include JSR affiliate companies Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005281/en/
Tim Lowery, President of JSR Life Sciences (Photo: Business Wire)
As president, Lowery will drive the company’s integrated global strategy and vision to provide a portfolio of innovative products, services and technologies to help partners develop and commercialize therapeutics and diagnostics that benefit global human health.
JSR Life Sciences provides strategic leadership of JSR’s biotech and life sciences-focused businesses and, along with its affiliates, employs more than 2400 employees. Lowery is replacing Eric R. Johnson who took over as CEO of JSR Corporation in Tokyo, Japan and president of JSR North America Holding Company, Inc. on June 18.
“I’m excited and humbled by the confidence JSR and Eric have shown in me,” said Lowery. “We’re a company of many parts, but with unified vision and purpose. I look forward to developing inter-company collaborations and innovation to bring that vision into reality.”
In addition to president of JSR Life Sciences, Lowery is an officer of JSR Corporation, chairman of the KBI Biopharma board of directors and a Selexis and Crown Bioscience board member. Prior to his promotion, Lowery served as General Manager of JSR Corporation’s bioprocess materials business and as CEO of MBL International, a JSR Life Sciences company.
“There is tremendous potential among our JSR Life Sciences companies, especially as they begin to collaborate,” said Johnson. “Tim and I have a long history of working together and I am fully confident that his experience and leadership are the right fit to build our vision for JSR’s life sciences business.”
About JSR Life Sciences, LLC
JSR Life Sciences, LLC is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop and deliver products to treat disease and improve the quality of life for patients. Based in Sunnyvale, CA, JSR Life Sciences operates a network of manufacturing facilities, R&D labs and sales offices in key markets throughout North America, Europe and Asia-Pacific.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005281/en/
Contact information
Missy Bindseil
JSR North America Holdings, Inc.
JSR Life
Sciences, LLC
830-237-9527
mbindseil@jsr-nahq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Launches Go Wild Podcast, Featuring Inspiring Brand Ambassadors and Spokespeople That Have Redefined the Game30.4.2025 11:00:00 EEST | Press release
Global sports company PUMA launches the ‘Go Wild Podcast’ as the brand continues to amplify its ‘Go Wild’ philosophy. The first initial episodes are hosted by sprint and hurdle legend Colin Jackson and will feature intimate interviews with a collective of high-profile ambassadors, athletes, and influencers associated with PUMA – also known as The PUMA Wild Ones - who embody PUMA’s philosophy to Go Wild by fearlessly redefining their fields in sport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430906610/en/ Global sports company PUMA launches the ‘Go Wild Podcast’ as the brand continues to amplify its ‘Go Wild’ philosophy. The first episode begins with a compelling conversation between Colin Jackson and the fastest man in the world, Usain Bolt, in a 30-minute sit-down interview. Listeners can expect an upbeat and playful conversation, diving into moments of triumph, emotional highs, and breakthroughs that have defined B
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 09:00:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 08:30:00 EEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including prioritisation of sharehol
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 04:00:00 EEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 23:03:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2025: Sales were $1.01 billion, flat in US dollars and up 2 percent in constant currency, compared
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom